BeiGene (BGNE) - Stock Price & Dividends

Exchange: USA Stocks • Country: Cayman Islands • Currency: USD • Type: Common Stock • ISIN: US07725L1026

BeiGene, Ltd. is a global biotechnology company that specializes in developing and distributing oncology medications. They offer a broad range of products for various types of cancers, including blood cancers, solid tumors, and leukemias. Their flagship products like BRUKINSA and Tislelizumab have made significant strides in cancer treatment.

Aside from their current pharmaceuticals, BeiGene, Ltd. is actively working on expanding their portfolio by developing new drugs to combat different types of cancers. Some of their promising ventures include Zanubrutinib, Ociperlimab, and Surzebiclimab, among others. These developments underline their commitment to advancing cancer treatment options.

Collaboration is key for BeiGene, Ltd., as they have established partnerships with several prominent companies within the industry like Amgen Inc., Novartis AG, and Bristol Myers Squibb company. These collaborations aim to leverage collective expertise and resources to drive innovation and bring more effective treatments to cancer patients.

Founded in 2010 and headquartered in Grand Cayman, the Cayman Islands, BeiGene, Ltd.'s dedication to oncology research and development is evident through their diverse product pipeline and strategic alliances. To learn more about their initiatives, you can visit their website at

Drawdown (Underwater) Chart

Drawdown / Underwater Chart for BeiGene (BGNE) - Stock Price & Dividends

BGNE Stock Overview

Market Cap in USD 16,661m
Sector Healthcare
Industry Biotechnology
GiC SubIndustry Biotechnology
TER 0.00%
IPO / Inception 2016-02-03

BGNE Stock Ratings

Growth 5y -0.49
Fundamental -5.29
Dividend -
Rel. Performance vs Sector -7.41
Analysts 4.57/5
Fair Price Momentum 110.67 USD
Fair Price DCF -

BGNE Dividends

Yield 12m 0.00%
Yield on Cost 5y 0.00%
Dividends CAGR 5y 0.00%
Payout Consistency 0.0%

BGNE Growth Ratios

Growth 12m -48.99%
Growth Correlation 12m -70%
Growth Correlation 3m -10%
CAGR 5y 1.85%
Sharpe Ratio 12m -1.13
Alpha vs SP500 12m -69.47
Beta vs SP500 5y weekly 0.88
ValueRay RSI 6.45
Volatility GJR Garch 1y 56.49%
Price / SMA 50 -15.25%
Price / SMA 200 -25.91%
Current Volume 200.1k
Average Volume 20d 164.9k

External Links for BGNE Stock

Wall Street JournalBenzingaYahoo Finance
X (Twitter)Stocktwits
Fund Manager Positions
What is the price of BGNE stocks?
As of April 18, 2024, the stock is trading at USD 131.86 with a total of 200,058 shares traded.
Over the past week, the price has changed by -11.95%, over one month by -21.74%, over three months by -21.42% and over the past year by -50.20%.
What is the forecast for BGNE stock price target?
According to ValueRays Forecast Model, BGNE BeiGene will be worth about 122.8 in April 2025. The stock is currently trading at 131.86. This means that the stock has a potential downside of -6.91%.
Issuer Forecast Upside
Wallstreet Target Price 273.5 107.4%
Analysts Target Price 292.5 121.8%
ValueRay Target Price 122.8 -6.91%